Antibody conjugate radioimmunotherapy of superficial bladder cancer

Antibody conjugate radioimmunotherapy of superficial bladder cancer

The administration of antibody conjugates for cancer therapy is now proving to be of clinical value. We are currently undertaking a programme of clinical studies using the monoclonal antibody C595 (IgG3) which reacts with the MUC1 glycoprotein antigen that is aberrantly expressed in a high proportion of bladder tumours. Radioimmunoconjugates of the C595 antibody have been produced with high radiolabelling efficiency and immunoreactivity using Tc-99m and In-111 for diagnostic imaging, and disease staging and the cytotoxic radionuclides Cu-67 and Re-188 for therapy of superficial bladder cancer. A Phase I/II therapeutic trail involving the intravesical administration of antibody directly into the bladder has now begun.

Saved in:
Bibliographic Details
Main Authors: Perkins,Alan, Hopper,Melanie, Murray,Andrea, Frier,Malcolm, Bishop,Mike
Format: Digital revista
Language:English
Published: Instituto de Tecnologia do Paraná - Tecpar 2002
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132002000500012
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-89132002000500012
record_format ojs
spelling oai:scielo:S1516-891320020005000122002-10-18Antibody conjugate radioimmunotherapy of superficial bladder cancerPerkins,AlanHopper,MelanieMurray,AndreaFrier,MalcolmBishop,Mike Antibody radioimmunotherapy bladder cancer The administration of antibody conjugates for cancer therapy is now proving to be of clinical value. We are currently undertaking a programme of clinical studies using the monoclonal antibody C595 (IgG3) which reacts with the MUC1 glycoprotein antigen that is aberrantly expressed in a high proportion of bladder tumours. Radioimmunoconjugates of the C595 antibody have been produced with high radiolabelling efficiency and immunoreactivity using Tc-99m and In-111 for diagnostic imaging, and disease staging and the cytotoxic radionuclides Cu-67 and Re-188 for therapy of superficial bladder cancer. A Phase I/II therapeutic trail involving the intravesical administration of antibody directly into the bladder has now begun.info:eu-repo/semantics/openAccessInstituto de Tecnologia do Paraná - TecparBrazilian Archives of Biology and Technology v.45 n.spe 20022002-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132002000500012en10.1590/S1516-89132002000500012
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Perkins,Alan
Hopper,Melanie
Murray,Andrea
Frier,Malcolm
Bishop,Mike
spellingShingle Perkins,Alan
Hopper,Melanie
Murray,Andrea
Frier,Malcolm
Bishop,Mike
Antibody conjugate radioimmunotherapy of superficial bladder cancer
author_facet Perkins,Alan
Hopper,Melanie
Murray,Andrea
Frier,Malcolm
Bishop,Mike
author_sort Perkins,Alan
title Antibody conjugate radioimmunotherapy of superficial bladder cancer
title_short Antibody conjugate radioimmunotherapy of superficial bladder cancer
title_full Antibody conjugate radioimmunotherapy of superficial bladder cancer
title_fullStr Antibody conjugate radioimmunotherapy of superficial bladder cancer
title_full_unstemmed Antibody conjugate radioimmunotherapy of superficial bladder cancer
title_sort antibody conjugate radioimmunotherapy of superficial bladder cancer
description The administration of antibody conjugates for cancer therapy is now proving to be of clinical value. We are currently undertaking a programme of clinical studies using the monoclonal antibody C595 (IgG3) which reacts with the MUC1 glycoprotein antigen that is aberrantly expressed in a high proportion of bladder tumours. Radioimmunoconjugates of the C595 antibody have been produced with high radiolabelling efficiency and immunoreactivity using Tc-99m and In-111 for diagnostic imaging, and disease staging and the cytotoxic radionuclides Cu-67 and Re-188 for therapy of superficial bladder cancer. A Phase I/II therapeutic trail involving the intravesical administration of antibody directly into the bladder has now begun.
publisher Instituto de Tecnologia do Paraná - Tecpar
publishDate 2002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132002000500012
work_keys_str_mv AT perkinsalan antibodyconjugateradioimmunotherapyofsuperficialbladdercancer
AT hoppermelanie antibodyconjugateradioimmunotherapyofsuperficialbladdercancer
AT murrayandrea antibodyconjugateradioimmunotherapyofsuperficialbladdercancer
AT friermalcolm antibodyconjugateradioimmunotherapyofsuperficialbladdercancer
AT bishopmike antibodyconjugateradioimmunotherapyofsuperficialbladdercancer
_version_ 1756423669418033152

Similar Items